{
    "clinical_study": {
        "@rank": "72075", 
        "arm_group": [
            {
                "arm_group_label": "AMG 151", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 1, randomized, double-blind, placebo-controlled, 2-way crossover study to\n      evaluate the effect of AMG 151 on 24-hour ambulatory blood pressure and glucose levels in\n      subjects with type 2 diabetes mellitus who are on a stable regimen of metformin alone,\n      metformin and a dipeptidyl peptidase-4 inhibitor (DPP4), metformin and a thiazolidinedione\n      (TZD), or metformin, a DPP4, and a TZD for a minimum of 3 months prior to randomization."
        }, 
        "brief_title": "Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Subjects with type 2 diabetes mellitus\n\n          -  On a stable regimen of metformin alone, metformin and a DPP4, metformin and a TZD, or\n             metformin, a DPP4, and a TZD for a minimum of 3 months prior to randomization\n\n          -  Body mass indices > 25 and < 45 kg/m2\n\n          -  Hemoglobin A1c levels \u2265 7.0% and \u2264 11.0% at screening\n\n          -  Fasting C-peptide levels \u2265 0.2 nmol/L at screening\n\n          -  Subject with a history of hypertension must be on a stable antihypertensive treatment\n             (s) (type of medication, dose, and regimen) for at least 6 weeks prior to the first\n             dose of investigational product\n\n          -  Other criteria may apply\n\n        Exclusion Criteria\n\n          -  Subject has type 1 diabetes mellitus or history of type 1 diabetes mellitus\n\n          -  Subject has had 2 or more emergency room visits or hospitalizations due to poor\n             glucose control in the 6 months prior to screening\n\n          -  Poorly controlled hypertension defined as diastolic pressure \u2265 95 mmHg or systolic \u2265\n             155 mmHg (confirmed by a repeat assessment) at screening\n\n          -  Triglycerides \u2265 400 mg/dL (4.52 mmol/L) at screening\n\n          -  Use of any known cytochrome P450 (CYP) inducers within 30 days or 5 half-lives\n             (whichever is longer), prior to receiving the first dose of investigational product.\n\n          -  Use of any known inhibitors of CYP3A4/P-glycoprotein within the 14 days or 5 half\n             lives (whichever is longer) prior to receiving the first dose of investigational\n             product\n\n          -  Other criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755442", 
            "org_study_id": "20120189"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "AMG 151", 
                "description": "Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.", 
                "intervention_name": "AMG 151", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ambulatory blood pressure", 
            "Type 2 diabetes"
        ], 
        "lastchanged_date": "April 19, 2013", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "San Diego", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92161"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Double-blind, Randomized, 2-Way Crossover, Placebo-controlled Study to Investigate the Effect of AMG 151 on 24-hour Ambulatory Blood Pressure and Glucose Levels in Subjects With Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mean 24-hour systolic blood pressure", 
            "safety_issue": "Yes", 
            "time_frame": "After 14 days of AMG 151 or placebo treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755442"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean 24-hour diastolic blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "After 14 days of AMG 151 or placebo treatment"
            }, 
            {
                "measure": "Mean 24-hour heart rate", 
                "safety_issue": "Yes", 
                "time_frame": "After 14 days of AMG 151 or placebo treatment"
            }, 
            {
                "measure": "24-hour concentration time profile of glucose level from continuous glucose monitoring", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and day 14 of each period"
            }, 
            {
                "measure": "Fasting plasma glucose and fructosamine", 
                "safety_issue": "No", 
                "time_frame": "After 13 days of AMG 151 or placebo treatment"
            }, 
            {
                "measure": "Plasma glucose 2 hours after time 0 of  mixed meal tolerance test", 
                "safety_issue": "No", 
                "time_frame": "After 13 days of AMG 151 or placebo treatment"
            }, 
            {
                "measure": "4-hour concentration time profile of glucose after the mixed meal tolerance test", 
                "safety_issue": "No", 
                "time_frame": "After 13 days of AMG 151 or placebo treatment"
            }, 
            {
                "measure": "Safety end points will include the incidence of treatment emergent adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 Months"
            }, 
            {
                "measure": "Serum AMG 151 concentration", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 Months"
            }, 
            {
                "measure": "Safety end points will include laboratory safety tests.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 Months."
            }, 
            {
                "measure": "Safety end points will include vital signs.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 Months"
            }, 
            {
                "measure": "Safety end points will include ECGs.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 Months"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013", 
        "why_stopped": "Amgen determined no further need for this study."
    }
}